PBLA — Panbela Therapeutics Share News
0.000.00%
HealthcareHighly SpeculativeMicro Cap
Panbela rises on positive DSMB feedback for cancer therapy study
Brief: Panbela Announces Preliminary Safety Analysis For Aspire Trial
Brief: Panbela Announces Paces S0820 Phase Iii Trial Passes Pre-Planned Futility Analysis
Brief: Panbela Announces Closing Of Approximately $8.5 Million Public Offering
U.S. STOCKS ON THE MOVE-Squarespace, NaaS Technology, American International Group
U.S. STOCKS ON THE MOVE-Virgin Galactic Holdings, Hospital stocks, Dollar General
Panbela plunges to record low after $8.5 mln public offering
Panbela plunges to record low after $8.5 mln public offering
Panbela plunges after $8.5 mln public offering
Brief: Panbela Therapeutics Announces Pricing Of ~$8.5 Mln Public Offering
U.S. STOCKS ON THE MOVE-Rio Tinto, BurgerFi International, Aclaris Therapeutics
U.S. STOCKS ON THE MOVE-Comerica, copper miners, Journey Medical
Brief: Panbela Announces Sponsored Research Agreement
Panbela Therapeutics rises on research agreement for blood cancer treatment
Brief: Panbela Announces 1-For-30 Reverse Stock Split Effective June 1, 2023
Panbela Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Panbela Provides Business Update And Reports Q1 2023 Financial Results
Panbela Therapeutics Inc expected to post a loss of 54 cents a share - Earnings Preview
Brief: Panbela Therapeutics Enrolles First Patient In Phase II Trial Of Cpp-1X-T For Onset Type I Diabetes